Postoperative adjuvant chemotherapy in surgically staged grade 3 endometrial cancer.
BACKGROUND
The effectiveness of postoperative adjuvant chemotherapy for surgically staged grade 3 endometrial cancer was investigated.


METHODS
Sixty-three consecutive patients with grade 3 endometrial cancer (49 with surgical stage I-II disease and 14 with stage III disease) were treated surgically. Postoperatively, 40 patients (63.5%) were treated with a chemotherapy regimen consisting of ifosfamide, epiadriamycin, and cisplatin scheduled for 3-5 cycles. No patient underwent radiotherapy.


RESULTS
Recurrence developed in 8 out of the 63 patients, all within two years. Six of the 8 recurrences were found to be extrapelvic lesions. Recurrences occurred predominantly at distant sites in the absence of pelvic radiation. Estimated 5-year disease-free survival rates were 89.8% for patients with surgical stage I-II disease, 78.6% for those with surgical stage III disease, and 87.3% overall.


CONCLUSIONS
The current study suggests the potential role of adjuvant chemotherapy alone in grade 3 endometrial cancer.
Takeshima
Nobuhiro
N
Department of Gynecology, Cancer Institute Hospital, Tokyo, Japan. nobuhiro.takeshima@jfcr.or.jp
Ota
Tsuyoshi
T
Omatsu
Kohei
K
Hasumi
Katsuhiko
K
Takizawa
Ken
K
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D018572:Disease-Free Survival; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007044:Hysterectomy; D007069:Ifosfamide / Q000008:administration & dosage; D008875:Middle Aged; D009367:Neoplasm Staging; D016896:Treatment Outcome
D015251:Epirubicin; D002945:Cisplatin; D007069:Ifosfamide